Alyeska Investment Group
TARA icon

Alyeska Investment Group’s Protara Therapeutics TARA Stock Holding History

Alyeska Investment Group’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Sell
39,726
-310,274
-89% -$1.48M ﹤0.01% 648
2026
Q1 		$1.82M Hold
350,000
– – 0.01% 550
2025
Q4 		$1.87M Buy
+350,000
New +$1.95M 0.01% 524
2021
Q2 		– Sell
-109,405
Closed -$1.72M – 830
2021
Q1 		$1.72M Buy
109,405
+35,000
+47% +$649K 0.02% 495
2020
Q4 		$1.8M Sell
74,405
-125,595
-63% -$2.71M 0.03% 381
2020
Q3 		$3.37M Buy
+200,000
New +$4.64M 0.05% 299
2015
Q1 		– Sell
-1,157
Closed -$481K – 577
2014
Q4 		$481K Buy
+1,157
New +$467K 0.01% 444

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Alyeska Investment Group's TARA Position: Q2 2026 in Review

Alyeska Investment Group reduced its Protara Therapeutics (TARA) stake by 89% in Q2 2026, selling an estimated $1.48M and leaving 39,726 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Alyeska Investment Group first reported a position in TARA in Q4 2014 and has held it in 7 quarters since. The position peaked at $3.37M in Q3 2020. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Alyeska Investment Group held 39,726 shares of Protara Therapeutics worth $152K as of Q2 2026.
  • Alyeska Investment Group sold 310,274 Protara Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Protara Therapeutics made up ﹤0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #648 holding.
  • Alyeska Investment Group first reported a position in Protara Therapeutics in Q4 2014 and has held it in 7 quarters since.
  • Alyeska Investment Group's Protara Therapeutics position peaked at $3.37M in Q3 2020.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.